What C94 covers · when clinicians use it
ICD-10 code C94 identifies Other leukemias of specified cell type in the U.S. ICD-10-CM clinical and billing record set. It sits within the Neoplasms chapter (C00–D49), the section that groups related diagnoses so providers, payers, and public-health agencies report them consistently. Clinicians and medical coders apply C94 when an encounter's findings match the Other leukemias of specified cell type description, attaching it to the patient record so downstream insurance claims, payer audits, quality reporting, and epidemiological surveillance all reference the same standardized diagnosis. The ICD-10-CM is maintained by the Centers for Medicare & Medicaid Services and the CDC's National Center for Health Statistics, with an updated official code set released each U.S. fiscal year — always verify C94 against the current CMS/CDC release and your payer's documentation guidance before final use. This page summarizes documentation context for C94 and is a coding reference, not clinical, diagnostic, or billing advice.
C94 refers to Other leukemias of specified cell type, a classification of cancers that affect the lymphatic system, bone marrow, and blood-forming tissues. These hematologic malignancies vary by cell origin—B-cell, T-cell, plasma cell, or myeloid—and range in severity and progression. Accurate ICD10 coding is crucial for tracking disease subtype, progression, and treatment response.
Symptoms
- Swollen lymph nodes – Often painless, in neck, armpit, or groin
- Fatigue – Due to anemia or bone marrow suppression
- Fever or night sweats – Common systemic “B symptoms”
- Unexplained weight loss – A key warning sign in blood cancers
- Bleeding or bruising – Due to low platelet count in leukemia
- Frequent infections – From low white blood cell counts
- Bone pain – Especially in multiple myeloma
Diagnosis
Diagnosis of Other leukemias of specified cell type includes blood tests (CBC, flow cytometry), bone marrow biopsy, lymph node biopsy, and imaging (CT, PET scans). Genetic and immunophenotyping studies help classify the specific subtype and guide targeted therapies. Monitoring may also involve minimal residual disease (MRD) testing.
ICD10 Code Usage
ICD10 code C94 is used in hematology and oncology for classifying and managing lymphomas, leukemias, and other blood cancers. These codes support documentation for cancer registries, clinical trials, insurance billing, and multidisciplinary treatment planning.
Related Codes
- C81 – Hodgkin lymphoma
- C82 – Follicular lymphoma
- C83 – Non-follicular lymphoma
- C84 – Mature T/NK-cell lymphomas
- C85 – Other specified and unspecified types of non-Hodgkin lymphoma
- C86 – Other specified types of T/NK-cell lymphoma
- C88 – Malignant immunoproliferative diseases and certain other B-cell lymphomas
- C90 – Multiple myeloma and malignant plasma cell neoplasms
- C91 – Lymphoid leukemia
- C92 – Myeloid leukemia
- C93 – Monocytic leukemia
- C95 – Leukemia of unspecified cell type
- C96 – Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue
FAQs
Q1: What is ICD10 code C94?
A: It refers to Other leukemias of specified cell type, used to classify blood cancers and lymphoproliferative disorders in medical systems.
Q2: What are the major types of blood cancers?
A: Lymphomas, leukemias, and plasma cell neoplasms like multiple myeloma.
Q3: Can these conditions be cured?
A: Many types are treatable or curable, especially if detected early and matched with the right therapy.
Q4: What treatments are used?
A: Chemotherapy, radiation, stem cell transplant, immunotherapy, and targeted therapies.
Q5: Who manages treatment?
A: Hematologists and oncologists, often in specialized cancer centers.
Conclusion
ICD10 code C94 ensures precise classification and tracking of Other leukemias of specified cell type. Proper coding enhances diagnosis, facilitates appropriate treatment selection, and contributes to cancer surveillance and research. It’s an essential component of comprehensive cancer care.